Business
grifols
Business
Grífols buys extra 40% stake in Kiro Grífols for €12.8m
Catalan pharmaceutical multinational continues to add to its R&D+i portfolio on back of acquiring minority stake in US firm GigaGen at start of July
Society
Catalonia offers to house European Medicines Agency
Business
Grífols acquires 20% of American multinational Singulex for $50 million
Business
Catalan pharmaceutical Grifols to buy 45% of California-based Alkahest for almost $40 million
Business
Catalan pharmaceutical giant Grifols sees a 23% jump in net profit in the first half of 2014
Business
Catalan pharmaceutical Grífols unveils world´s largest plasma fractionation plant in North Carolina
Politics
Business associations give their "unconditional support" to Catalonia's self-determination
Politics
Ibex 35 pharmaceutical Grífols' President supports the Catalan President's plans
Business
Grífols’ profits up 35% in 2013 to reach over €345 million
Society
Grífols and ACE Foundation to test an Alzheimer’s vaccine in January 2014
Business
Grífols buys 21.3% of biotech company TiGenix for €12 million
Business
Grífols buys part of Novartis Diagnostics for $1.68 billion
Business
Grífols makes a profit of €182.2 million during the first half of 2013, an increase of 36.9% on last year
Business
Catalan Grífols buys 60% of Progenika Biopharma and posts a net profit of €257 million
The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.